Watch Erdafitinib Videos

Erdafitinib for bladder cancer: more to come following FDA approval

ETCTN 10483: erdafitinib and EV in FGFR3/2-altered urothelial cancer

THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations

Balversa tablets (Erdafitinib) how to use: Uses, Dosage, Side Effects, Contraindications

NORSE: erdafitinib and cetrelimab in metastatic urothelial cancer

Erdafitinib demonstrates efficacy in intermediate-risk NMIBC with FGFR alterations

The future role of erdafitinib in advanced urothelial carcinoma

Erdafitinib and enfortumab vedotin in pretreated FGFR2/3-mutant bladder cancer

THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations

#ESMO21 Highlights on erdafitinib in adv. urothelial cancer with FGFRa alterations: The NORSE study

Managing toxicities in advanced urothelial cancers: insights on EV and erdafitinib

Erdafitinib: one more tool for bladder cancer

Important Side Effects with Erdafitinib & T DXd

TAR-210 erdafitinib intravesical delivery system in non-muscle invasive bladder cancer

Targeted therapy effective for patients with advanced bladder cancer and specific gene mutations

Introducing the therascreen FGFR RGQ RT-PCR Kit and Day-One Readiness at Insight Molecular Labs

ASCO 2023 Highlights on erdafitinib in metastatic urothelial cancer with select FGFR alterations

Phase II Study of Erdafitinib in Tumors with FGFR Amplifications and Mutations or Fusions

The future of the TAR-210 delivery system for erdafitinib in NMBIC

BLC2001: erdafitinib for the treatment of metastatic urothelial carcinoma